Trump administration secures historic Medicare drug price cuts, challenging Big Pharma's grip

"Medicare officials have announced aggressively negotiated price cuts for 15 of the program's most expensive prescription drugs - projecting a staggering 44% reduction from last year's prices and potential savings of $12 billion. The announcement made on Tuesday, Nov. 25, represents the most significant action to date in a concerted push by the Trump administration to dismantle the longstanding status quo of exorbitant pharmaceutical costs that have burdened American seniors for decades."

"This authority was first initiated under the Biden administration's 2022 Inflation Reduction Act (IRA), but is now being implemented with renewed vigor by the current administration. It marks a radical departure from a decades-old legal prohibition that prevented Medicare from negotiating drug prices."

"The policy has faced fierce legal challenges from the pharmaceutical industry, which argues that government price setting stifles innovation, but courts have so far upheld the government's authority to negotiate. The prices set by Medicare are expected to create a new benchmark, potentially leading to lower drug costs across the entire U.S. healthcare system as private insurers demand similar discounts."

Medicare has successfully negotiated substantial price reductions on 15 expensive prescription drugs, achieving an average 44% price cut from the previous year and generating approximately $12 billion in projected savings. This represents the first time the federal government has directly exercised its purchasing power to negotiate drug prices, a capability granted by the 2022 Inflation Reduction Act. The negotiated prices take effect in 2027 and are expected to reduce out-of-pocket costs for seniors while improving Medicare's financial position. Despite fierce legal challenges from the pharmaceutical industry claiming government price-setting inhibits innovation, courts have upheld the government's negotiation authority. These Medicare-negotiated prices are anticipated to establish a benchmark that could drive lower drug costs throughout the entire U.S. healthcare system as private insurers seek comparable discounts.

Read at Natural Health News